Press Releases

CALGARY, Alberta, May 09, 2024 (GLOBE NEWSWIRE) -- Prospera Energy Inc. ("Prospera" or the "Corporation") (TSX.V:PEI, OTC:GXRFF, FRA:OF6B, OF6B.SG, OF6B.BE) announces that further to its news release dated April 25, 2024, the Corporation's principal regulator, the Alberta Securities Commission (the "ASC") granted a management cease trade order (the "MCTO") on May 7, 2024, under National Policy 12-203 Management Cease Trade Orders ("NP 12-203"). Pursuant to the MCTO,... (continue reading...)

HONG KONG, May 9, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International", "Fosun" or "the Company") has successfully completed the refinancing of its USD804 million loan due on 7 May 2024.  As part of the refinancing process, the Company has successfully obtained a new syndicate loan of USD597 million, while the remaining was repaid through its own funds.

The Company collaborated closely with its banking partners and the... (continue reading...)

NASSAU, Bahamas, May 9, 2024 /PRNewswire/ -- OKX, a leading crypto exchange and Web3 technology company, has issued updates for May 9, 2024.

OKX Adjusts Components for Several Indices

OKX has adjusted the components for several indices to improve market liquidity and index stability. The adjustments took place at 10:00 am - 12:00 am UTC on May 9, 2024.... (continue reading...)

LIMA, PERU, May 9, 2024 /PRNewswire/ -- Corporación Financiera de Desarrollo S.A. ("COFIDE") today announced the expiration and final results as of 5:00 p.m. (New York City time) on May 9, 2024 (the "Expiration Date") of the previously announced cash tender offer (the "Offer") for any and all of its outstanding 5.250% Fixed-to-Floating Rate Subordinated Notes due 2029 (the "Notes") issued by COFIDE on the terms and subject to the conditions set forth in... (continue reading...)

Shenzhen, China--(Newsfile Corp. - May 9, 2024) - Kexing Biopharm recently took an important step forward in cancer therapy. Kexing Biopharm signed a cooperation agreement with Kerui Pharma, a subsidiary of Qingfeng Pharmaceutical Group (hereinafter referred to as "Qingfeng Pharma"), for the international commercialization of Olaparib Tablets. The agreement grants Kexing Biopharm the rights to commercialize Qingfeng Pharma-manufactured Olaparib Tablets in 10 oversea... (continue reading...)